Table 3.

Adjusted ORs of VEGF genotypes and haplotypes for NSCLC risks

All cases (n = 1,900) vs. controls (n = 1,458)
Male cases (n = 981) vs. controls (n = 638)
Female cases (n = 919) vs. controls (n = 820)
OR (95% CI)POR (95% CI)POR (95% CI)P
Genotypes
VEGF −460C/T
    TT1.01.01.0
    CT+CC1.16 (0.96-1.40)0.121.07 (0.81-1.40)0.651.27 (0.98-1.65)0.07
VEGF −405C/G
    GG1.01.01.0
    CG+CC1.14 (0.96-1.36)0.131.27 (0.99-1.63)0.061.04 (0.82-1.32)0.73
VEGF +936C/T
    CC1.01.01.0
    CT+TT1.05 (0.87-1.27)0.591.13 (0.87-1.50)0.370.99 (0.27-1.29)0.95
Haplotypes*
Global test0.540.030.68
    CGC1.01.01.0
    TCC1.02 (0.88-1.17)0.841.15 (0.94-1.42)0.100.91 (0.74-1.11)0.34
    TGC0.88 (0.75-1.04)0.140.81 (0.63-1.02)0.080.93 (0.74-1.17)0.53
    CGT0.98 (0.74-1.31)0.890.90 (0.59-1.36)0.611.04 (0.69-1.55)0.87
    TCT1.14 (0.84-1.55)0.391.15 (0.72-1.85)0.551.04 (0.69-1.57)0.85
  • NOTE: Adjusted for age, gender, smoking status, pack-years of smoking, and years since smoking cessation (if ex-smoker).

  • * The combined haplotype frequencies (in the order of −460C/T, +405C/G, +936C/T) <5% were not included in the analysis.